Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Radka Obermannová(Masaryk University), Elizabeth Smyth(National Health Service), Magnus Nilsson(Karolinska University Hospital), Arndt Vogel(Princess Margaret Cancer Centre), Nicole C.T. van Grieken(Cancer Center Amsterdam), Andrés Cervantes(INCLIVA Health Research Institute), María Alsina(Vall d'Hebron Hospital Universitari), Trevor Leong(The University of Melbourne), Florian Lordick(Leipzig University)
Annals of Oncology
July 30, 2022
10.1016/j.annonc.2022.07.003
Cited by 646

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Gastric cancer
|The Lancet|2020|4.8k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k